Serving To Educate Primary Care Clinicians On Metabolic Issues
Home
Subscribe
Feedback
Contact Us
Evidence Based Medicine
Medical Education
Metabolic Diseases
About Us
PCMG CME
PCMG Non-CME
Resources
Needs Survey
Commentaries
Survey
SCAFP Updates CKD Pre Survey
Which of the following is TRUE regarding current ADA/KDIGO recommendations for SGLT2 inhibitor use in CKD?
[ Required ]
Recommended only in people with eGFR =45 mL/min/1.73m2
Recommended for continuation until initiation of dialysis or transplant
Recommended only in patients with elevated A1c
Evidence of benefit is based on observational data only
Which SGLT2 inhibitor has been studied in a population with CKD and low levels of albuminuria (e.g., <200 mg/g), without diabetes?
[ Required ]
Canagliflozin
Dapagliflozin
Empagliflozin
All of the above
How confident do you feel in your answer to the previous question?
[ Required ]
Select...
Very confident
Confident
Somewhat confident
Not confident
Submit